# Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration

> **NCT02036723** · PHASE3 · WITHDRAWN · sponsor: **Biocad**

## Conditions studied

- Wet Age-related Macular Degeneration

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT02036723
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2016-03
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02036723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02036723, "Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02036723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*